Bulletin | Potential Adverse Health Effects Related to Marijuana-infused Products Containing Corydalis yanhusuo | August 12, 2022

To:Marijuana Establishments and Medical Marijuana Treatment Centers licensed pursuant to 935 CMR 500.000 and 501.000, Certifying Healthcare Providers, Registered Qualifying Patients and Personal Caregivers, and Consumers
From: Shawn Collins, Executive Director
Date: August 12, 2022
Subject: Marijuana-infused Products containing Corydalis yanhusuo

The Cannabis Control Commission (Commission) provides notice that there are potential adverse health effects allegedly related to the consumption of Marijuana-infused Products (MIPs) containing Corydalis rhizome extract (Corydalis), a.k.a. Corydalis yanhusuo.

The Commission has become aware of a recent notification from the Colorado Department of Revenue’s Marijuana Enforcement Division indicating that consumption of an MIP in Colorado marketed as 1906 Midnight Drops may have led to certain adverse health issues, including potential liver injury.  A similar report was recently received from a Massachusetts medical provider concerning 1906 Midnight Drops, an MIP available for sale in the Commonwealth and manufactured using the ingredient Corydalis.  Because Corydalis has been associated with an elevated risk of liver injury, a.k.a., hepotoxicity, and may pose a risk to the public health, safety, and welfare, the Commission is currently investigating this ingredient, including one of its alkaloids, tetrahydropalmatine (THP).  At this time, the Commission is not exercising its authority to issue a product recall or limit the sale of specific products or product categories.  Instead, this bulletin is intended to inform the public of its active and ongoing investigation into this ingredient.

The Commission’s regulations require all MIPs to have a product label listing its ingredients.  Any patient or consumer who experiences adverse health effects from consuming 1906 Midnight Drops, or any marijuana product containing Corydalis, should seek immediate medical attention and may report the event to the Commission by calling (774) 415-0200 or via email at Inspections@CCCMass.com.

Questions regarding this notice may be directed to Commission@CCCMass.com.